The DNA Damage Response and Tumorigenesis in the Brain

大脑中的 DNA 损伤反应和肿瘤发生

基本信息

项目摘要

Summary - Project 2 Brain tumors are the most common solid malignancies of childhood and are a leading cause of cancer-related death in children. 15-20% of pediatric CNS tumors are high-grade gliomas (HGG), and individuals with these tumors have a 2-year survival rate of 10-30%. Despite extensive research into the molecular basis of gliomagenesis, current therapies remain ineffective, and the majority of patients die from their disease. More effective therapeutic strategies are likely to come from a detailed understanding of glioma pathogenesis. We have developed a unique series of new HGG mouse models, relevant to the human disease, which are characterized by a range of histopathology reflective of the specific defect in the DNA damage response. In Aim 1 of this proposal we will determine the genomic alterations and gene expression profiles that underpin these gliomas, particularly in the context of human disease and other mouse glioma models, either established or under development in other projects in this program. We will also determine the basis for tumor heterogeneity in these models by ascertaining the detailed developmental origins of these gliomas and the relative susceptibility of different neural progenitors to transformation. These analyses will illuminate critical aspects of the pathogenesis of gliomas for which there is a paucity of definitive information. Finally, we will also determine cooperativity in these models with other mutations found in human pediatric HGG, including histone H3 mutations, taking advantage of novel models generated by other projects within the program. In Aim 2 we propose experiments to establish which DNA repair pathways are critical for genome stability at different cortical progenitor stages and how this is linked to chromatin. Because histone mutations and other epigenetic alterations have recently been identified as causative molecular changes in pediatric HGG, our study will be of central importance for understanding connections between DNA damage signaling, epigenetics and tumorigenesis. In Aim 3 we will determine if DNA breaks associated with early replicating fragile sites account for DNA structural alterations central to gliomagenesis. Collectively, findings from this study will provide fundamental new information to delineate glioma biology that will be important for developing targeted therapy for these diseases.
摘要-项目2 脑肿瘤是儿童期最常见的实体恶性肿瘤,并且是癌症相关疾病的主要原因。 儿童死亡。15-20%的儿童CNS肿瘤是高级别胶质瘤(HGG),患有这些肿瘤的个体 肿瘤的2年存活率为10- 30%。尽管广泛的研究,以分子基础, 尽管神经胶质瘤的发生率很高,但目前的治疗仍然无效,并且大多数患者死于其疾病。更 有效的治疗策略可能来自对胶质瘤发病机制的详细了解。我们 已开发出一系列独特的与人类疾病相关的新型HGG小鼠模型,其中包括 其特征在于反映DNA损伤反应中特定缺陷的一系列组织病理学。在 本提案的目的1,我们将确定基因组改变和基因表达谱, 这些神经胶质瘤,特别是在人类疾病和其他小鼠神经胶质瘤模型的背景下, 或在本计划的其他项目中开发。我们还将确定肿瘤的基础 通过确定这些神经胶质瘤的详细发育起源和这些模型的异质性, 不同神经祖细胞对转化的相对易感性。这些分析将阐明关键的 神经胶质瘤的发病机制方面,有一个明确的信息缺乏。最后我们将 还确定这些模型与人类儿科HGG中发现的其他突变的协同性,包括 组蛋白H3突变,利用该计划内其他项目产生的新模型。在 目的2:我们提出实验来确定哪些DNA修复途径对基因组稳定性至关重要, 不同的皮质祖细胞阶段以及这与染色质的联系。因为组蛋白突变和其他 表观遗传学改变最近被确定为儿童HGG的致病分子变化,我们 这项研究对于理解DNA损伤信号传导、表观遗传学 和肿瘤发生。在目标3中,我们将确定DNA断裂是否与早期复制的脆性位点有关 解释了神经胶质瘤形成的核心DNA结构改变。总的来说,这项研究的结果将 提供基本的新信息来描述胶质瘤生物学,这对于开发靶向药物非常重要 治疗这些疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER J MCKINNON其他文献

PETER J MCKINNON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER J MCKINNON', 18)}}的其他基金

Genome Stability in Glia & Disease
神经胶质细胞基因组稳定性
  • 批准号:
    10650409
  • 财政年份:
    2022
  • 资助金额:
    $ 44.08万
  • 项目类别:
Genome Stability in Glia & Disease
神经胶质细胞基因组稳定性
  • 批准号:
    10522673
  • 财政年份:
    2022
  • 资助金额:
    $ 44.08万
  • 项目类别:
Third Genome Dynamics in the Neurosciences Conference
神经科学会议上的第三届基因组动力学
  • 批准号:
    7806347
  • 财政年份:
    2010
  • 资助金额:
    $ 44.08万
  • 项目类别:
Genomic Instability in Mouse Medulloblastoma
小鼠髓母细胞瘤的基因组不稳定性
  • 批准号:
    8056130
  • 财政年份:
    2003
  • 资助金额:
    $ 44.08万
  • 项目类别:
Genomic Instability in Mouse Medulloblastoma
小鼠髓母细胞瘤的基因组不稳定性
  • 批准号:
    8459546
  • 财政年份:
    2003
  • 资助金额:
    $ 44.08万
  • 项目类别:
The DNA Damage Response and Tumorigenesis in the Brain
大脑中的 DNA 损伤反应和肿瘤发生
  • 批准号:
    8854876
  • 财政年份:
    2003
  • 资助金额:
    $ 44.08万
  • 项目类别:
Genomic Instability in Mouse Medulloblastoma
小鼠髓母细胞瘤的基因组不稳定性
  • 批准号:
    8375492
  • 财政年份:
    2003
  • 资助金额:
    $ 44.08万
  • 项目类别:
Genomic Instability in Mouse Medulloblastoma
小鼠髓母细胞瘤的基因组不稳定性
  • 批准号:
    8459548
  • 财政年份:
    2003
  • 资助金额:
    $ 44.08万
  • 项目类别:
The DNA Damage Response and Tumorigenesis in the Brain
大脑中的 DNA 损伤反应和肿瘤发生
  • 批准号:
    9277198
  • 财政年份:
    2003
  • 资助金额:
    $ 44.08万
  • 项目类别:
Genomic Instability in Mouse Medulloblastoma
小鼠髓母细胞瘤的基因组不稳定性
  • 批准号:
    7647492
  • 财政年份:
    2003
  • 资助金额:
    $ 44.08万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.08万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了